Guggenheim Securities, the investment banking arm of Guggenheim Partners, has formed a strategic alliance with Australia’s ...

Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Guggenheim analyst Michael Morris maintained a Buy rating on Paramount Global Class B (PARA – Research Report) yesterday and set a price target ...

Three men are on trial for stealing a toilet in an audacious raid. You didn’t misread that sentence. A toilet.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM – Research Report), ...

LG and the Guggenheim New York proudly announce Ayoung Kim as the 2025 LG Guggenheim Award recipient. Kim is the third artist to be recognized as part of the LG Guggenheim Art and Technology ...

Sempra (NYSE:SRE – Get Free Report) had its price target dropped by Guggenheim from $95.00 to $87.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” ...

Set on La Gorce Island, a Miami Beach residence listed for $88 million—dubbed Okto—spans nearly 16,000 square feet with 260 ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

Wingstop (NASDAQ:WING – Get Free Report) was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating in ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...